MedTrace Logo

Platelet-rich Plasma (PRP) Injection for Treatment of Erectile Function

NCT04050020 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-10-20

No results posted yet for this study

Summary

The primary objective of the present study is to investigate and compare the treatment efficacy of PRP injection vs placebo treatment in men with mild-moderate vasculogenic ED, as measured by IIEF.The secondary objective of the present clinical trial is to study the adverse events and safety of the PRP injection treatment in vasculogenic ED patients

Conditions

  • Erectile Dysfunction Due to Arterial Insufficiency

Interventions

BIOLOGICAL

Platelet-Rich Plasma (PRP)

All subjects of this group will receive 2 sessions of PRP penile injection with 30 +/- 3 day treatment interval, 10 ml of PRP will be injected at each session.

BIOLOGICAL

Normal saline injection

All subjects of this group will receive 2 sessions of normal saline penile injection with 30 +/- 3 day treatment interval for all subjects, 10 ml of normal saline will be injected at each session.

Sponsors & Collaborators

  • European Society for Sexual Medicine

    collaborator UNKNOWN

  • Institute for the Study of Urological Diseases, Greece

    lead OTHER

Principal Investigators

  • Dimitrios Hatzichristou, Prof. · G.Gennimatas General Hospital, Thessaloniki,Greece

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-02
Primary Completion
2020-03-26
Completion
2020-09-24

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04050020 on ClinicalTrials.gov